Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Patriarca, Francesca  [Clear All Filters]
2024
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AMaria, Cutini I, Dodero A, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024.
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kröger N, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024.
2023
Marcon C, Bertone A, Mauro S, Mestroni R, Battaglia G, Pizzano U, Facchin G, De Martino M, Isola M, Patriarca F, et al. Stem Cells mobilization and collection in allogeneic related and unrelated donors: a single center experience with focus on plerixafor. Transfus Apher Sci. 2023:103845.
2022
Mariotti J, Raiola AMaria, Evangelista A, Harbi S, Patriarca F, Carella MAngelo, Martino M, Risitano A, Busca A, Giaccone L, et al. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.
2021
Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, et al. GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. Transplant Cell Ther. 2021.
2020
Pastore D, Bruno B, Carluccio P, De Candia MStella, Mammoliti S, Borghero C, Chierichini A, Pavan F, Casini M, Pini M, et al. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Ann Hematol. 2020.
Tacchetti P, Pantani L, Patriarca F, Petrucci MTeresa, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020;7(12):e861-e873.
Di Nora C, Sponga S, Ferrara V, Patriarca F, Fanin R, Nalli C, Lechiancole A, Vendramin I, Livi U. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation. J Cardiovasc Med (Hagerstown). 2020.
Mariotti J, Raiola AMaria, Evangelista A, Carella AMichele, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
2019
Sorà F, Di Grazia C, Chiusolo P, Raiola AMaria, Bregante S, Mordini N, Olivieri A, Iori APaola, Patriarca F, Grisariu S, et al. Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan Fludarabine (BUFLU) or Thiotepa Busulfan Fludarabine (TBF): a retrospective study. Biol Blood Marrow Transplant. 2019.
Girmenia C, Lazzarotto T, Bonifazi F, Patriarca F, Irrera G, Ciceri F, Aversa F, Citterio F, Cillo U, Cozzi E, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO and AMCLI societies. Clin Transplant. 2019:e13666.
Peccatori J, Mastaglio S, Giglio F, Greco R, Crocchiolo R, Patriarca F, Forno B, Deola S, Assanelli A, Stanghellini MTeresa Lup, et al. Clofarabine and Treosulfan as conditioning for matched related and unrelated HSCT: results from the phase II trial "Clo3o". Biol Blood Marrow Transplant. 2019.
Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.
2018
Patriarca F, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MChiara, Bosi A, Russo D, Narni F, Messina G, et al. Busulfan or thiotepa based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group. Biol Blood Marrow Transplant. 2018.
2016
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374(1):43-53.
2014
Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MTeresa, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, et al. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2014;371(10):895-905.
Dozzo M, Battista MLisa, Medeot M, Sperotto A, Fanin R, Patriarca F. Long lasting remission after haploidentical stem cell transplantation and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin's lymphoma. Leuk Lymphoma. 2014:1-8.